FULC
Fulcrum TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Composite grade F from latest DB weights. Momentum 2.0 / Value 57.1
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.2.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
2
Value
57
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $3.40
Why
Momentum2 · Δ7d +0.5
Value57 · Δ7d +0.2
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
2
40% active weight
Current posture
7d trendFlat
Δ7d
+0.5
Δ21d
+0.8
Value
57
60% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
-0.2
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 2.0 / Value 57.1
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$245.21M
Beta
3.19
Shares Out
66.63M
P/E (TTM) · Derived
-3.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.86
Rev YoY
-100.0%
EPS YoY
-12.3%
Gross Margin
+98.1%
Op Margin
-15.6%
Net Debt
-$345.86M
Current Ratio
34.33
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology